Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | KIF11 | P52732 | 7/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.40 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA6 | P23280 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27468704 | 0.84 | KIF11 (0.43) | CYP1A2MEN1KMT2AKIF11CYP2C19 | |
| SCHEMBL305912 | 0.82 | CYP1A2 (0.70) | CYP1A2MEN1KMT2AKIF11CYP2C19 | |
| SCHEMBL2089243 | 0.82 | CYP1A2 (0.70) | CYP1A2MEN1KMT2AKIF11CYP2C19 | |
| SCHEMBL2089245 | 0.82 | CYP1A2 (0.70) | CYP1A2MEN1KMT2AKIF11CYP2C19 | |
| SCHEMBL25398908 | 0.82 | MEN1 (0.53) | CYP1A2MEN1KMT2ACYP3A4ALDH1A1 | |
| SCHEMBL27843752 | 0.80 | CYP1A2 (0.68) | CYP1A2MEN1KMT2AKIF11CYP2C19 | |
| Water SCHEMBL8329268 | 0.80 | CYP1A2 (0.68) | CYP1A2MEN1KMT2AKIF11CYP2C19 | |
| Hydrochloric Acid SCHEMBL1630962 | 0.80 | CYP1A2 (0.68) | CYP1A2MEN1KMT2AKIF11CYP2C19 | |
| SCHEMBL11732389 | 0.80 | MEN1 (0.54) | CYP1A2MEN1KMT2AKIF11CYP3A4 | |
| SCHEMBL27338628 | 0.79 | MEN1 (0.71) | CYP1A2MEN1KMT2AKIF11CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1390343-B1 | NOVEL RETINOID DERIVATIVES AND AN ANTI-CANCER PHARMACEUTICAL COMPOSITION COMPRISING SAID COMPOUNDS | CHEBIGEN CO LTD (KR) | 2009-10-14 | — | — | EP | disclosed |
| US-7166744-B2 | Retinoid derivatives and methods for producing said compounds and anti-cancer pharmaceutical composition comprising said compounds | CHEBIGEN CO., LTD. (KR) | 2007-01-23 | — | — | US | disclosed |
| EP-1390343-A4 | NOVEL RETINOID DERIVATIVES AND METHODS FOR PRODUCING SAID COMPOUNDS AND AN ANTI-CANCER PHARMACEUTICAL COMPOSITION COMPRISING SAID COMPOUNDS | CHEBIGEN CO LTD (KR) | 2005-06-22 | — | — | EP | disclosed |
| EP-1390343-A1 | NOVEL RETINOID DERIVATIVES AND METHODS FOR PRODUCING SAID COMPOUNDS AND AN ANTI-CANCER PHARMACEUTICAL COMPOSITION COMPRISING SAID COMPOUNDS | Chebigen Co., Ltd. (KR) | 2004-02-25 | — | — | EP | disclosed |
| US-20030171339-A1 | Novel retinoid derivatives and methods for producing said compounds and anti-cancer pharmaceutical composition comprising said compounds | CHEBIGEN CO., LTD. (KR) | 2003-09-11 | — | — | US | disclosed |
| WO-2002096857-A1 | NOVEL RETINOID DERIVATIVES AND METHODS FOR PRODUCING SAID COMPOUNDS AND AN ANTI-CANCER PHARMACEUTICAL COMPOSITION COMPRISING SAID COMPOUNDS | CHEBIGEN CO., LTD. (KR) | 2002-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171339-A1 | Novel retinoid derivatives and methods for producing said compounds and anti-cancer pharmaceutical composition comprising said compounds | RXRB, RARB, RXRA | CYP1A2 771/4885MEN1 2083/4885KMT2A 3305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.